Milan, Italy (December 2, 2025)
Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced the participation of its Chief Executive Officer, Marco Ferroni, in the institutional event promoted by DGPI-UIBM on Industrial Property and Technology Transfer.
The event will be held on December 4, 2025, in Rome, Italy. Marco Ferroni will join the roundtable with leading representatives from research and industry to discuss how to enhance the value of industrial property, address emerging opportunities and challenges, and explore how universities and companies turn research into innovation. MgShell’s goal is to strengthen its dialogue with institutional stakeholders and deepen collaborations that support the development and future implementation of its technology.
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
